Colleen Cavanagh
Rock Hill, SCNPI 1932748621
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 366 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,342 and has fallen 92.8% since, to $168 in 2025.
Across 366 payments — averaging $15.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$677
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$636
- Supernus Pharmaceuticals, Inc.$542
- Lundbeck LLC$504
- Takeda Pharmaceuticals U.S.A., Inc.$342
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,56698%
- Education$972%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 104 | $1,295 |
| Otsuka America Pharmaceutical, Inc. | 36 | $677 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 27 | $636 |
| Supernus Pharmaceuticals, Inc. | 45 | $542 |
| Lundbeck LLC | 37 | $504 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $342 |
| Sunovion Pharmaceuticals Inc. | 15 | $185 |
| Neos Therapeutics, LP | 10 | $177 |
| Alkermes, Inc. | 9 | $160 |
| Johnson & Johnson | 8 | $146 |
| Tris Pharma Inc | 7 | $144 |
| Merck | 8 | $122 |
| Teva Pharmaceuticals USA, Inc. | 1 | $112 |
| Sanofi-aventis U.S. LLC | 3 | $69 |
| Sanofi Pasteur Inc. | 3 | $64 |
| Adlon Therapeutics L.p. | 3 | $59 |
| Idorsia Pharmaceuticals US Inc | 3 | $53 |
| Neurocrine Biosciences, Inc. | 3 | $50 |
| Eisai Inc. | 2 | $44 |
| Seqirus USA Inc | 2 | $38 |
| Ironshore Pharmaceuticals Inc. | 2 | $34 |
| GSK | 2 | $31 |
| Noven Therapeutics, LLC | 2 | $30 |
| Mayne Pharma Commercial LLC | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Organon | 1 | $21 |
| AstraZeneca | 1 | $18 |
| Almatica Pharma LLC | 1 | $16 |
| Phadia US Inc. | 1 | $16 |
| Bausch Health US, LLC | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$125
- ABILIFY MAINTENA$120
- AUSTEDO$112
- VRAYLAR$101
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.